Colchicine

Colchicine has been studied in 62 papers since 2022: 7 trials and 9 observational studies in people, 5 in animals, 2 in cells, 35 reviews; 47 in the past year. It is an approved medicine. The newest story, Nov 3, 2026: “Colchicine not linked to cardiovascular risk in a Chinese cohort”.

InterventionApproved 2009

62 papers study it17 more mention it57 findingsUpdated

PubChemChEBIMeSH

23 new papers in 30 daysSee all 78 papers on colchicine

At a glance

Colchicine reduces age-associated neuronal decline in worms in preprints from one group; reviews describe fewer cardiovascular events in people with coronary disease. Independent labs report reduced leukocyte counts in human trials; most C-reactive protein tests show no clear effect, but a hypertension trial reports a decrease. Some authors have company affiliations, and some trials across its uses are company-sponsored.

57 findings in 29 papers from 2022 to 2026, 17 of them since April 2026

Independent labs found the same change in people. 17 independent labs in 10 countries; 158 trials, 2 about aging, 48 with no results posted.

“Forty-five deaths were cardiovascular (colchicine versus placebo: 20 [0.7%] versus 25 [0.9%], HR, 0.80; 95% CI, 0.44-1.44)”
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trialInternational journal of cardiology2022doi:10.1016/j.ijcard.2022.12.026

1 of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: a single group.
  • 17 independent labs in 10 countries
  • 1 finding against
  • 158 trials, 2 about aging, 48 with no results posted
  • Funders: Gangstedfonden and others
  • 5 of 47 findings with company ties
  • 14 of 158 trials sponsored by its developers
  • Human trial7
  • Humans8
  • Animals3
  • Model organisms2
  • Cells2
  • In silico1

6 studies gave colchicine to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on aortic FDG uptakeAdjusted mean change 0.05 versus 0.01 with placebo; p=0.38

down: Decreases neutrophil-to-lymphocyte ratioAdjusted mean change −0.36 versus −0.08; p=0.033

down: Decreases blood pressureSystolic change 0.88 versus 4.94 mmHg (p=0.046); diastolic change 1.41 versus 4.35 mmHg (p=0.048)

Randomized trial24 weeks111 peopleChronic coronary artery diseaseCardiovascular research, Nov 7, 2026

no change: Has no effect on cardio-ankle vascular indexBetween-group difference 0.17, 95% CI -0.18 to 0.51; p=0.35

no change: Has no effect on C-reactive proteinMean changes 0.42 versus 0.25 mg/L; p=0.78

Randomized trial6 months60 peopleBoth40 to 60 years; mean 53.2 yearsMidlife adults; type 2 diabetes without established atherosclerotic cardiovascular diseaseESC Congress 2026 abstract, Oct 26, 2026

no change: Has no effect on left ventricular systolic and diastolic function

down: Decreases tricuspid annular plane systolic excursion-0.26 cm (95% CI -0.40 to -0.11); values remained within the normal clinical range

down: Decreases leukocyte countBetween-group difference in percent change: -8.0% (95% CI -13.5 to -2.5); p=0.004

Randomized trial6 months150 peopleadultsWell-controlled hypertension without other known cardiovascular diseaseESC Congress 2026 abstract, Oct 26, 2026

down: Decreases leukocyte countP=0.02

no change: Has no effect on C-reactive protein

Randomized trial4 weeks48 peopleBothmean age 70±6 yearsOlder adults; Patient cohortsESC Congress 2026 abstract, Oct 26, 2026

no change: Has no effect on carotid-femoral pulse wave velocityBetween-group difference in change -0.1 m/s (95% CI -0.5 to 0.3); p=0.53

up: Increases office systolic blood pressureBetween-group difference in change +5.7 mmHg (95% CI 1.0 to 10.5); p=0.018

down: Decreases C-reactive proteinBetween-group difference in percent change -39.8% (95% CI -59.1 to -11.4); p=0.010

Randomized trialsix months150 peopleBoth64.5 (±8.0) yearsOlder adults; pharmacologically treated hypertension without cardiovascular diseaseEuropean journal of preventive cardiology, Oct 16, 2026

What did studies of colchicine find?

39

Studies of colchicine measured 39 outcomes; the most studied are C-reactive protein (3 studies), inflammation (2) and leukocyte count (2).

C-reactive protein

no changein humans2downin humans1

3 studies
  1. Colchicine showed no clear effect on C-reactive protein in humans (type 2 diabetes; compared with placebo) (Mean changes 0.42 versus 0.25 mg/L; p=0.78).

    “Similarly, mean changes in hs-CRP did not differ significantly (0.42 vs 0.25 mg/L, p=0.78).”

    Human trialtype 2 diabetes; compared with placebo0.6 mg daily6 months40% malesn = 60

    Efficacy of low-dose colchicine on arterial stiffness via cardio-ankle vascular index in type 2 diabetes: a randomized controlled trial

    ESC Congress 2026 abstract

  2. Colchicine showed no clear effect on C-reactive protein in humans.

    “did not modify C-reactive protein or interleukin-6”

    Human trialoral0.5 mg once daily4 weeksn = 48

    Colchicine alters protein networks in a coronary disease trial

    ESC Congress 2026 abstract

  3. Colchicine decreases C-reactive protein in humans (Between-group difference in percent change -39.8% (95% CI -59.1 to -11.4); p=0.010).

    “hsCRP decreased significantly in the colchicine group compared with the placebo group”

    Human trialpharmacologically treated hypertension without cardiovascular disease; compared with placebo0.5 mg dailysix monthsn = 150

    Effect of Colchicine on Arterial Stiffness in Patients With Hypertension: The COlchicine HypERtENsion Trial (COHERENT)

    European journal of preventive cardiology

More on C-reactive protein

Inflammation

downin humans1downin rats1

2 studies
  1. Colchicine inhibits inflammation in stable CAD with CHIP.

    “baseline correlations between clonal burden and inflammatory protein modules were markedly attenuated during colchicine exposure”

    Human trialin stable CAD with CHIPoral0.5 mg once daily4 weeksn = 48

    Colchicine alters protein networks in a coronary disease trial

    ESC Congress 2026 abstract

  2. Colchicine decreases inflammation in rats (spontaneously hypertensive rats).

    “reduced inflammation and extracellular matrix remodelling in mesenteric resistance arteries”

    Animalsspontaneously hypertensive ratsmesenteric resistance artery4 weeks

    Colchicine in chronic coronary artery disease: effects on vascular glucose uptake, inflammation, remodeling and blood pressure

    Cardiovascular research

More on Inflammation

Leukocyte count

downin humans2

2 studies
  1. Colchicine decreases leukocyte count in humans (Between-group difference in percent change: -8.0% (95% CI -13.5 to -2.5); p=0.004).

    “Leukocyte count decreased significantly in the colchicine group compared with the placebo group after 6 months treatment”

    Human trialwell-controlled hypertension without other known cardiovascular disease; compared with placebo0.5 mg daily6 monthsn = 150

    Effects of colchicine on cardiac structure and function in patients with hypertension: a prespecified secondary analysis of the COlchicine HypERtENsion Trial (COHERENT)

    ESC Congress 2026 abstract

  2. Colchicine decreases leukocyte count in humans (P=0.02).

    “Colchicine exposure reduced leukocyte counts (P=0.02)”

    Human trialoral0.5 mg once daily4 weeksn = 48

    Colchicine alters protein networks in a coronary disease trial

    ESC Congress 2026 abstract

More on Leukocyte count

Stroke

no changein humans1HR 0.91

1 study
  1. Colchicine was not clearly linked with stroke in humans (HR 0.91, 95% CI 0.81–1.01; P = 0.076).

    “No significant differences were observed for myocardial infarction (HR 1.15; 95% CI 0.96–1.37; P = 0.121) or stroke (HR 0.91; 95% CI 0.81–1.01; P = 0.076).”

    HumansType 2 diabetes mellitus and gout without prior coronary artery disease; propensity-matched comparison with non-users

    Colchicine use was associated with reduced all-cause mortality in patients with diabetic gout without prior coronary artery disease: A propensity-matched nationwide cohort study

    PloS one

More on Stroke

Myocardial infarction

no changein humans1HR 1.15

1 study
  1. Colchicine was not clearly linked with myocardial infarction in humans (HR 1.15, 95% CI 0.96–1.37; P = 0.121).

    “No significant differences were observed for myocardial infarction (HR 1.15; 95% CI 0.96–1.37; P = 0.121) or stroke (HR 0.91; 95% CI 0.81–1.01; P = 0.076).”

    HumansType 2 diabetes mellitus and gout without prior coronary artery disease; propensity-matched comparison with non-users

    Colchicine use was associated with reduced all-cause mortality in patients with diabetic gout without prior coronary artery disease: A propensity-matched nationwide cohort study

    PloS one

More on Myocardial infarction

Vasodilator responses

upin rats1

1 study
  1. Colchicine improves vasodilator responses in rats (spontaneously hypertensive rats).

    “while enhancing vasodilator responses.”

    Animalsspontaneously hypertensive ratsmesenteric resistance artery4 weeks

    Colchicine in chronic coronary artery disease: effects on vascular glucose uptake, inflammation, remodeling and blood pressure

    Cardiovascular research

Extracellular matrix remodeling

downin rats1

1 study
  1. Colchicine decreases extracellular matrix remodeling in rats (spontaneously hypertensive rats).

    “reduced inflammation and extracellular matrix remodelling in mesenteric resistance arteries”

    Animalsspontaneously hypertensive ratsmesenteric resistance artery4 weeks

    Colchicine in chronic coronary artery disease: effects on vascular glucose uptake, inflammation, remodeling and blood pressure

    Cardiovascular research

More on Extracellular matrix remodeling

Blood pressure

downin humans1

1 study
  1. Colchicine decreases blood pressure in humans (Systolic change 0.88 versus 4.94 mmHg (p=0.046); diastolic change 1.41 versus 4.35 mmHg (p=0.048)).

    “attenuation of increases in systolic (adjusted mean change 0.88 mmHg vs. 4.94 mmHg; p=0.046) and diastolic (1.41 mmHg vs. 4.35 mmHg; p=0.048) blood pressure.”

    Human trialchronic coronary artery disease; attenuation of increases in secondary and exploratory analyses0.6 mg daily24 weeksn = 111

    Colchicine in chronic coronary artery disease: effects on vascular glucose uptake, inflammation, remodeling and blood pressure

    Cardiovascular research

Neutrophil-to-lymphocyte ratio

downin humans1

1 study
  1. Colchicine decreases neutrophil-to-lymphocyte ratio in humans (chronic coronary artery disease; secondary and exploratory analyses) (Adjusted mean change −0.36 versus −0.08; p=0.033).

    “colchicine was associated with a reduction in neutrophil-to-lymphocyte ratio”

    Human trialchronic coronary artery disease; secondary and exploratory analyses0.6 mg daily24 weeksn = 111

    Colchicine in chronic coronary artery disease: effects on vascular glucose uptake, inflammation, remodeling and blood pressure

    Cardiovascular research

More on Neutrophil-to-lymphocyte ratio

Aortic FDG uptake

no changein humans1

1 study
  1. Colchicine showed no clear effect on aortic FDG uptake in humans (chronic coronary artery disease) (Adjusted mean change 0.05 versus 0.01 with placebo; p=0.38).

    “Colchicine did not reduce aortic FDG uptake compared with placebo”

    Human trialchronic coronary artery diseaseascending aorta0.6 mg daily24 weeksn = 111

    Colchicine in chronic coronary artery disease: effects on vascular glucose uptake, inflammation, remodeling and blood pressure

    Cardiovascular research

More on Aortic FDG uptake

Estimated glomerular filtration rate

no changein humans1

1 study
  1. Colchicine showed no clear effect on estimated glomerular filtration rate in humans.

    “There was no observable change between groups in NT-proBNP or eGFR at 6 months treatment”

    Human trialwell-controlled hypertension without other known cardiovascular disease; compared with placebo0.5 mg daily6 monthsn = 150

    Effects of colchicine on cardiac structure and function in patients with hypertension: a prespecified secondary analysis of the COlchicine HypERtENsion Trial (COHERENT)

    ESC Congress 2026 abstract

More on Estimated glomerular filtration rate

NT-proBNP

no changein humans1

1 study
  1. Colchicine showed no clear effect on NT-proBNP in humans.

    “There was no observable change between groups in NT-proBNP or eGFR at 6 months treatment”

    Human trialwell-controlled hypertension without other known cardiovascular disease; compared with placebo0.5 mg daily6 monthsn = 150

    Effects of colchicine on cardiac structure and function in patients with hypertension: a prespecified secondary analysis of the COlchicine HypERtENsion Trial (COHERENT)

    ESC Congress 2026 abstract

More on NT-proBNP

Tricuspid annular plane systolic excursion

downin humans1

1 study
  1. Colchicine decreases tricuspid annular plane systolic excursion in humans (-0.26 cm (95% CI -0.40 to -0.11); values remained within the normal clinical range).

    “a decrease of tricuspid annular plane systolic excursion (TAPSE) in the colchicine group (TAPSE, -0.26 cm [95% CI: -0.40 to -0.11]; p<0.001)”

    Human trialwell-controlled hypertension without other known cardiovascular disease; compared with placeboheart0.5 mg daily6 monthsn = 150

    Effects of colchicine on cardiac structure and function in patients with hypertension: a prespecified secondary analysis of the COlchicine HypERtENsion Trial (COHERENT)

    ESC Congress 2026 abstract

More on Tricuspid annular plane systolic excursion

Left ventricular systolic and diastolic function

no changein humans1

1 study
  1. Colchicine showed no clear effect on left ventricular systolic and diastolic function in humans.

    “colchicine had no observable impact on echocardiographic measurements of left ventricular systolic or diastolic function after 6 months of treatment.”

    Human trialwell-controlled hypertension without other known cardiovascular disease; compared with placeboleft ventricle0.5 mg daily6 monthsn = 150

    Effects of colchicine on cardiac structure and function in patients with hypertension: a prespecified secondary analysis of the COlchicine HypERtENsion Trial (COHERENT)

    ESC Congress 2026 abstract

Cardio-ankle vascular index

no changein humans1

1 study
  1. Colchicine showed no clear effect on cardio-ankle vascular index in humans (Between-group difference 0.17, 95% CI -0.18 to 0.51; p=0.35).

    “At 6 months, the absolute change in CAVI did not differ significantly between groups.”

    Human trialtype 2 diabetes without established atherosclerotic cardiovascular disease; compared with placebo0.6 mg daily6 months40% malesn = 60

    Efficacy of low-dose colchicine on arterial stiffness via cardio-ankle vascular index in type 2 diabetes: a randomized controlled trial

    ESC Congress 2026 abstract

More on Cardio-ankle vascular index

All 39

What is colchicine linked with?

9

Studies link colchicine with 9 measures, among them mortality, cardiovascular events and atherosclerotic cardiovascular disease.

Mortality

downin humans2HR 0.58–0.74

2 studies
  1. Colchicine is associated with mortality in humans (8.01% versus 11.07%; HR 0.58, 95% CI 0.53–0.62).

    “All-cause mortality was significantly reduced in colchicine users”

    HumansType 2 diabetes mellitus and gout without prior coronary artery disease; propensity-matched comparison with non-users

    Colchicine use was associated with reduced all-cause mortality in patients with diabetic gout without prior coronary artery disease: A propensity-matched nationwide cohort study

    PloS one

  2. Colchicine is associated with mortality in humans (Chinese adults without prior cardiovascular disease initiating urate-lowering therapy) (HR 0.74, 95% CI 0.64–0.86).

    “All-cause mortality was lower among colchicine users (HR, 0.74; 95% CI, 0.64 to 0.86).”

    HumansChinese adults without prior cardiovascular disease initiating urate-lowering therapyMedian follow-up of 3.05 years

    Colchicine not linked to cardiovascular risk in a Chinese cohort

    BMC medicine

Cardiovascular events

downin humans2

2 studies
  1. Colchicine lowers the risk of cardiovascular events in humans (selected patients with atherosclerotic cardiovascular disease).

    “Cardiovascular outcome data support icosapent ethyl, low-dose colchicine, dual-pathway antithrombotic therapy, and further ApoB lowering in selected patients.”

    Reviewselected patients with atherosclerotic cardiovascular diseaselow-dose

    Residual cardiovascular risk beyond LDL-C in ASCVD: Biological drivers, biomarkers, and therapeutic strategies

    Acta pharmaceutica Sinica. B

  2. Colchicine lowers the risk of cardiovascular events in humans (23-31% risk reduction).

    “colchicine achieved 23-31% risk reduction”

    Review

    IMMUNOMODULATORS IN THE TREATMENT OF ATHEROSCLEROSIS AND OTHER CHRONIC HEART DISEASES: PROSPECTS AND RISKS

    Georgian medical news

Atherosclerotic cardiovascular disease

downin humans2

2 studies
  1. Colchicine lowers the risk of atherosclerotic cardiovascular disease in humans.

    “Specific approaches-such as IL-1β inhibition or low-dose colchicine-have shown benefit in reducing cardiovascular events”

    Reviewlow-dose

    Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies

    Immunological reviews

  2. Colchicine lowers the risk of atherosclerotic cardiovascular disease in humans (independent of lipid modification).

    “Clinical trials examining anti-inflammatory therapies, such as colchicine and interleukin-1β inhibitors (e.g., canakinumab), have demonstrated beneficial effects in reducing cardiovascular events independent of lipid modification.”

    Reviewindependent of lipid modification

    Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

More on Atherosclerotic cardiovascular disease

Cardiovascular disease

downin humans2

2 studies
  1. Colchicine lowers the risk of cardiovascular disease in humans.

    “targeted modulation of inflammatory pathways, such as IL-1β inhibition and colchicine therapy, can reduce cardiovascular events independent of lipid lowering.”

    Review

    Beyond cholesterol: targeting inflammatory biomarkers in cardiovascular disease

    Clinica chimica acta; international journal of clinical chemistry

  2. Colchicine lowers the risk of cardiovascular disease in humans (secondary cardiovascular prevention).

    “results from recent meta-analyses strongly support colchicine therapy for secondary cardiovascular prevention.”

    Reviewsecondary cardiovascular prevention

    Triglyceride-Rich Lipoproteins and Inflammation: Independent and Synergistic Roles in Cardiovascular Disease

    Current atherosclerosis reports

More on Cardiovascular disease

Composite of all-cause death, nonfatal myocardial infarction, and nonfatal stroke

downin humans1HR 0.71

1 study
  1. Colchicine is associated with composite of all-cause death, nonfatal myocardial infarction, and nonfatal stroke in humans (12.52% versus 15.03%; HR 0.71, 95% CI 0.66–0.75).

    “The primary composite outcome occurred in 12.52% of colchicine users versus 15.03% of non-users”

    HumansType 2 diabetes mellitus and gout without prior coronary artery disease; propensity-matched comparison with non-users

    Colchicine use was associated with reduced all-cause mortality in patients with diabetic gout without prior coronary artery disease: A propensity-matched nationwide cohort study

    PloS one

Transaminase

upin humans1

1 study
  1. Colchicine is associated with transaminase in humans (Observed during colchicine treatment, prompting discontinuation).

    “Colchicine was discontinued due to rising transaminases”

    HumansObserved during colchicine treatment, prompting discontinuation0.5 mg dailyfemalesn = 1

    Invisible Burden: Severe Premature Coronary Atherosclerosis Unmasked by Female-Specific and Inflammatory Risk Enhancers in an Asymptomatic South Asian Woman

    AHA Scientific Sessions 2026 abstract

More on Transaminase

Adverse events

downin humans1

1 study
  1. Colchicine lowers the risk of adverse events in humans (coronary artery disease).

    “Among patients with coronary artery disease, the use of colchicine has demonstrated significant risk reduction in adverse events, though with mixed results.”

    Reviewcoronary artery disease

    Coronary inflammation: Identification, clinical impact and possible therapeutical solutions

    International journal of cardiology

Major adverse cardiovascular events

downin humans1−23% relative risk reduction

1 study
  1. Colchicine lowers the risk of major adverse cardiovascular events in patients with recent myocardial infarction (23% relative risk reduction).

    “The Colchicine Cardiovascular Outcomes Trial (COLCOT) in patients with recent myocardial infarction (MI) and the Low-Dose Colchicine 2 (LoDoCo2) trial in patients with chronic coronary syndrome showed relative risk reductions of 23% and 31% for major adverse cardiovascular events (MACE).”

    Reviewin patients with recent myocardial infarction

    Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT

    Current atherosclerosis reports

Major adverse cardiac and cerebrovascular events

downin humans1OR 0.183

1 study
  1. Colchicine is linked with a lower risk of major adverse cardiac and cerebrovascular events in patients with inflammatory gout (adjusted OR 0.183, 95% CI 0.080–0.417).

    “Colchicine use was associated with significantly lower MACCE risk (adjusted OR 0.183, 95% CI 0.080–0.417, p<0.0001).”

    Humansin patients with inflammatory goutn = 2,367

    Colchicine Reduces Cardiovascular Events in Patients with Increased High-sensitivity C-reactive protein

    AHA Scientific Sessions 2025 abstract

Has colchicine been tested in people?

2 of 158 about aging

Yes: 7 trials and 9 observational studies in people have been published, and 158 trials are registered.

Approved

All 7

Repurposing

40 of 81

Every condition in trials

  • Pharmacokinetic

    Phase 4Results posted7 trials

  • Atrial Fibrillation New Onset

    Phase 4Completed2 trials

  • Colchicine Adverse Reaction

    Phase 4Completed2 trials

  • Percutaneous coronary intervention

    Phase 4Completed2 trials

  • C reactive protein

    Phase 4Status unknown1 trial

  • Elderly patients

    Phase 4Status unknown1 trial

All 17

Readouts due

Stopped

  • NCT03933007TerminatedGout Flares

    faillure of recrutement

  • NCT04008316TerminatedIga vasculitis

    Sponser decision

  • NCT02177266TerminatedPostpericardiotomy Syndrome

    Difficulty in recruiting patients

  • NCT03575572TerminatedUniventricular heart

    Staffing changes impacted by COVID-19 pandemic resulting in inadequate personnel to facilitate study.

  • NCT02926248Suspended

    Continuing IRB review was not submitted. Study was inactivated with the institutional IRB.

Who is developing colchicine?

1 company: Shanton Pharma Pte..

Companies

Trial sponsors

Funding

3 grants since 2020

National Heart, Lung, and Blood Institute$5.1MGouvernement du Canada | Canadian Institutes of Health ResearchCA$5.4M

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 6Feb 2026: 8Mar 2026: 3Apr 2026: 1May 2026: 1Jun 2026: 2Jul 2026: 3Aug 2026: 3Sep 2026: 2Oct 2026: 16Nov 2026: 1056 papers in 12 months
BMC Medicine

Colchicine not linked to cardiovascular risk in a Chinese cohort

Cardiovascular disease rates were 1.62 versus 1.59 per 100 person-years among colchicine users and non-users, respectively, after statistical adjustment.Cardiovascular disease rates were 1.62 versus 1.59 per 100 person-years among colchicine users and non-users, respectively, after statistical adjustment.

See all 78 papers on colchicine